Novel NF-κB inhibitors: a patent review (2011 – 2014)

Bibliography

• Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986;46:705-16
   PubMed Web of Science ®Google Scholar
• Verma IM, Stevenson JK, Schwarz EM, et al. Rel/NF-kappaB/IkappaB family: intimate tales of association and dissociation. Genes Dev 1995;9:2723-35
   PubMed Web of Science ®Google Scholar
• Ghosh S, May MJ, Kopp EB. NF-kappaB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-60
   PubMed Web of Science ®Google Scholar
• Gilmore TD. The Rel/NF-kappaB signal transduction pathway: introduction. Oncogene 1999;18:6925-37
   PubMed Web of Science ®Google Scholar
• Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-kappaB activity. Annu Rev Immunol 2000;18:621-63
   PubMed Web of Science ®Google Scholar
• May MJ, Ghosh S. Rel/NF-kappaB and IkappaB proteins: an overview. Semin Cancer Biol 1997;8:63-73
   PubMed Web of Science ®Google Scholar
• Kwak JH, Jung JK, Lee H. Nuclear factor-kappa B inhibitors; a patent review (2006-2010). Expert Opin Ther Pat 2011;21:1897-910
   PubMed Web of Science ®Google Scholar
• Vigo HV, Krappmann D, Hatada EN, et al. Shared pathways of IkappaB Kinase-Induced SCFβTrCP-mediated ubiquitination and degradation for the NF-kappaB Precursor p105 and IkappaBalpha. Mol Cell Biol 2001;21:1024-35
   PubMed Web of Science ®Google Scholar
• Baldwin ASJr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-83
   PubMed Web of Science ®Google Scholar
• Kelliher MA, Grimm S, Ishida Y, et al. The death-domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity 1998;8:297-303
   PubMed Web of Science ®Google Scholar
• Yang J, Lin Y, Guo Z, et al. The essential role of MEKK3 in TNF-induced NF-kappaB activation. Nat Immunol 2001;2:620-4
   PubMed Web of Science ®Google Scholar
• Matsushima A, Kaisho T, Rennert PD, et al. Essential role of nuclear factor (NF)-kappaB-inducing kinase and inhibitor of kappaB (IkappaB) kinase alpha in NF-kappaB activation through lymphotoxin beta receptor, but not through tumor necrosis factor receptor I. J Exp Med 2001;193:631-6
   PubMed Web of Science ®Google Scholar
• Li N, Karin M. Ionizing radiation and short wavelength UV activate NF-kappaB through two distinct mechanisms. Proc Natl Acad Sci USA 1998;95:13012-17
   PubMed Web of Science ®Google Scholar
• Ben-Neriah Y. Regulatory functions of ubiquitination in the immune system. Nature Immunol 2002;3:20-6
   PubMed Web of Science ®Google Scholar
• Joel LP, David B. Two pathways to NF-kappaB. Mol Cell 2002;10:693-701
   PubMedGoogle Scholar
• Hinz M, Krappmann D, Eichten A, et al. NF-kappaB Function in Growth Control: Regulation of Cyclin D1 Expression and G0/G1-to-S-Phase Transition. Mol Cell Biol 1999;19:2690-8
   PubMed Web of Science ®Google Scholar
• Gudkov AV. Modulating apoptosis. US8106005B2; 2012
   Google Scholar
• Shakhov A, Gudkov A. Methods of protecting against apoptosis using lipopeptides. US8008260B2; 2011
   Google Scholar
• Shakhov A, Gudkov A. Methods of protecting against apoptosis using lipopeptides. US8524668B2; 2013
   Google Scholar
• Shakhov A, Gudkov A. Methods of protecting against apoptosis using lipopeptides. US0237507A1; 2011
   Google Scholar
• Baltimore D, Ramakrishnan P. Use of sam68 for modulating signaling through the tnf receptor. WO058642A2; 2012
   Google Scholar
• Kumar A, Takada Y, Boriek AM, et al. Nuclear factor-kappaB: its role in health and disease. J Mol Med 2004;82:434-48
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001;107:135-42
   PubMed Web of Science ®Google Scholar
• Christman JW, Sadikot RT, Blackwell TS. The role of nuclear factor-kappaB in pulmonary diseases. Chest 2000;117:1482-7
   PubMed Web of Science ®Google Scholar
• Kumar A, Lnu S, Malya R, et al. Mechanical stretch activates nuclear factor-kappaB, activator protein-1, and mitogen-activated protein kinases in lung parenchyma: implications in asthma. FASEB J 2003;17:1800-11
   PubMed Web of Science ®Google Scholar
• Poynter ME, Irvin CG, Janssen-Heininger YM. Rapid activation of nuclear factor-kappab in airway epithelium in a murine model of allergic airway inflammation. Am J Pathol 2002;160:1325-34
   PubMed Web of Science ®Google Scholar
• Hart LA, Krishnan VL, Adcock IM, et al. Activation and localization of transcription factor, nuclear factor-kappaB, in asthma. Am J Respir Crit Care Med 1998;158:1585-92
   PubMed Web of Science ®Google Scholar
• Henderson WRJ, Chi EY, Eo JL, et al. A small molecule inhibitor of redox-regulated NF-kappaB and activator protein-1 transcription blocks allergic airway inflammation in a mouse asthma model. J Immunol 2002;169:5294-9
   PubMed Web of Science ®Google Scholar
• Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 1987;326:711-13
   PubMed Web of Science ®Google Scholar
• Hiscott J, Kwon H, Genin P. Hostile takeovers: viral appropriation of the NF-kappaB pathway. J Clin Invest 2001;107:143-51
   PubMed Web of Science ®Google Scholar
• Surabhi RM, Gaynor RB. RNA Interference directed against viral and cellular targets inhibits human immunodeficiency virus type 1 replication. J Virol 2002;76:12963-73
   PubMed Web of Science ®Google Scholar
• Kwon H, Pelletier N, DeLuca C, et al. Inducible expression of IkappaBalpha repressor mutants interferes with NF-kappaB activity and HIV-1 replication in Jurkat T cells. J Biol Chem 1998;273:7431-40
   PubMed Web of Science ®Google Scholar
• Kutsch O, Niederweis M, Wolschendorf F, et al. Latent human immunodeficiency virus reactivation. US0096054A1; 2013
   Google Scholar
• He G, Yu G-Y, Temkin V, et al. Hepatocyte IKKβ/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Canc. Cell 2010;17:286-97
   PubMed Web of Science ®Google Scholar
• Demchenko YN, Kuehl WM. A critical role for the NF-kappaB pathway in multiple myeloma. Oncotarget 2010;1:59-68
   PubMed Web of Science ®Google Scholar
• Sun HZ, Wang TW, Zang WJ, et al. Dehydroepiandrosterone-induced proliferation of prostatic epithelial cell is mediated by NF-kappaB via PI3K/AKT signaling pathway. J Endocrinol 2010;204:311-18
   PubMed Web of Science ®Google Scholar
• Galardi S, Mercatelli N, Farace MG, et al. NF-kappaB and c-Jun induce the expression of the oncogenic miR-221 and miR-222 in prostate carcinoma and glioblastoma cells. Nucl Acid Res 2011;39:3892-902
   PubMed Web of Science ®Google Scholar
• Santini D, Schiavon G, Vincenzi B, et al. Receptor Activator of NF-kappaB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One 2011;6:e19234
   PubMed Web of Science ®Google Scholar
• Costanzo A, Spallone G, Karin M. NF-kappaB, Ikb kinase and interacting signal networks in squamous cell carcinomas. In: Glick AB, Van Waes C, editors. Signaling pathways in squamous cancer. Chapter 10. Springer; Dordrecht: 2011. p. 201-22
   Google Scholar
• Valkov A, Sorbye SW, Kilvaer TK, et al. the prognostic impact of TGF-β1, Fascin, NF-kappaB and PKC-ζ expression in soft tissue sarcomas. PLoS One 2011;6:e17507
   PubMed Web of Science ®Google Scholar
• Markus DS, Dario CA. Combination therapies with mitochondrial-targeted anti-tumor agents. US0268722A1; 2011
   Google Scholar
• Kuwada KS. Compositions and methods for inhibiting NF-kappaB mediated tumorigenicity and adhesion dependent survival of cancer cells. US7989495B2; 2011
   Google Scholar
• Kuwada KS. Inhibitors of peritoneal seeding of cancer cells. US0251135A1; 2011
   Google Scholar
• Maeda S. Cancer metastasis inhibitor. WO013786A1; 2011
   Google Scholar
• Maeda S. Cancer metastasis inhibitor. US0183539A1; 2012
   Google Scholar
• Lavon I. Nucleic acid sequences comprising NF-kappaB binding site within O(6)-methyl guanine-DNA-methyltransferase (MGMT) promoter region and uses thereof for the treatment of cancer and immune-related disorders. US8299237B2; 2012
   Google Scholar
• Park H-Y, Son K-H, Shin D-H, Jeong K-S. Composition containing arazyme for the prevention and treatment of cancer. US0003204A1; 2012
   Google Scholar
• Gudkov VA. Use of toll-like receptor and agonist for treating cancer. US0208871A1; 2011
   Google Scholar
• Porco JAJr, Gerard B, Guilford J, et al. Synthesis of rocaglamide natural products via photochemical generation of oxidopyrylium species. US0065786A1; 2011
   Google Scholar
• Franzoso G, Carlson L, Xing L, et al. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 1997;11:3482-96
   PubMed Web of Science ®Google Scholar
• Weih DS, Yilmaz ZB, Weih F. Essential role of RelB in germinal center and marginal zone formation and proper expression of homing chemokines. J Immunol 2001;167:1909-19
   PubMed Web of Science ®Google Scholar
• Schafer PH, Bartlett JB, Zhang L-H, et al. Methods for the treatment of non-hodgkin’s lymphomas using lenalidomide, and gene and protein biomarkers as a predictor. US0223157A1; 2011
   Google Scholar
• Mason N, May M, Baldwin AS. Compositions and methods for treating an activated b-cell diffuse large b-cell lymphoma. US20130338080A1; 2012
   Google Scholar
• Makarov SS. NF-kappaB in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction. Arthritis Res 2001;3:200-6
   PubMedGoogle Scholar
• Kim D-W. Genes implicated in osteoarthritis and use thereof. WO093647A2; 2011
   Google Scholar
• Sookmyung Women’s University Industry Academic Cooperation Foundation. Anti-inflammatory composition containing a thiourea compound and a pharmaceutically acceptable salt thereof as an active ingredient. WO060594A2; 2012
   Google Scholar
• University of Rochester. Method of preventing development of psoriatic lesions. WO154684; 2012
   Google Scholar
• Bonetti B, Stegagno C, Cannella B, et al. Activation of NF-kappaB and c-jun transcription factors in multiple sclerosis lesions. Implications for oligodendrocyte pathology. Am J Pathol 1999;155:1433-8
   PubMed Web of Science ®Google Scholar
• Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1998;23:339-46
   Google Scholar
• Kaur S, Southall MD, Zivin RA, et al. Topical application of 1-hydroxyl 3,5-bis(4’hydroxyl styryl)benzene. WO004177A2; 2014
   Google Scholar
• Kaur S, Mahmood K, Southall MD. Compositions comprising substituted phenols and topical application thereof. WO004178A2; 2014
   Google Scholar
• Muto S, Nagano T, Sotome T, Itai A. Inflammatory cytokine release inhibitor. US8097759B2; 2012
   Google Scholar
• Thomas T, Sarkar F, Callewaert DM, et al. Composition and method for affecting cytokines and NF-kappaB. US0117122A1; 2011
   Google Scholar
• Thomas T, Sarkar F, Callewaert DM, et al. Composition and method for affecting cytokines and NF-kappaB. US0251698A1; 2013
   Google Scholar
• Kaltschmidt B, Uherek M, Wellmann H, et al. Inhibition of NF-kappaB potentiates amyloid β-mediated neuronal apoptosis. Proc Natl Acad Sci USA 1999;96:9409-14
   PubMed Web of Science ®Google Scholar
• Ellis RD, Goodlad JR, Limb GA, et al. Activation of nuclear factor kappa B in Crohn’s disease. Inflamm Res 1998;47:440-5
   PubMed Web of Science ®Google Scholar
• Thiele K, Bierhaus A, Autschbach F, et al. Cell specific effects of glucocorticoid treatment on the NF-kappaBp65/IkappaBalpha system in patients with Crohn’s disease. Gut 1999;45:693-704
   PubMed Web of Science ®Google Scholar
• National University Corporation Tottori University. Therapeutic agent for inflammatory bowel disease. WO038776A1; 2013
   Google Scholar
• Ehwa Womans University. Guggulsterone derivatives, a preparation method thereof, and a use thereof. KR1020090080474A; 2011
   Google Scholar
• Grilli M, Pizzi M, Memo M, et al. Neuroproteciton by aspirin and sodium salicylate through blockade of NF-B activation. Science 1996;274:1383-5
   PubMed Web of Science ®Google Scholar
• Palayoor ST, Bump EA, Calderwood SK, et al. Ibuprofen-mediated Reduction of Hypoxia-inducible Factors HIF-1alpha and HIF-2alpha in prostate cancer cells. Clin Cancer Res 1998;4:763-71
   PubMed Web of Science ®Google Scholar
• Takada Y, Bhardwaj A, Potdar P, et al. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004;23:9247-58
   PubMed Web of Science ®Google Scholar
• Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents’ aspirin and salicylate inhibit the activity of IkappaB kinase-β. Nature 1998;396:77-80
   PubMed Web of Science ®Google Scholar
• Letoha T, Somlai C, Takacs T, et al. A nuclear import inhibitory peptide ameliorates the severity of cholecystokinin-induced acute pancreatitis. World J Gasteroenterol 2005;11:990-9
   PubMed Web of Science ®Google Scholar
• Baltimore D, Sen R, Sharp PA, et al. Nuclear factors associates with transcriptional regulation. US005804374; 1998
   Google Scholar
• May MJ, Ghosh S, Findeis MA, et al. Anti-inflammatory compounds and uses thereof. US0071092A1; 2011
   Google Scholar
• May MJ, Ghosh S. Anti-inflammatory compounds and uses thereof. US0160119A1; 2011
   Google Scholar
• May MJ, Ghosh S. Anti-inflammatory compounds and uses thereof. US0101028A1; 2012
   Google Scholar
• May MJ, Ghosh S. Using polypeptide comprising a membrane translocation domain and a NF- kappaB Essential Modulator (NEMO) binding sequence; comprising a NEMO binding domain (NBD). US7872094B2; 2011
   Google Scholar
• Yamaoka S, Courtois G, Israel A, Weil R. Nucleotide sequence encoding a modulator of NF- κB. US0182811A1; 2011
   Google Scholar
• Li Jun Li X, Catron KM. Ikkalpha and ikkβ specific inhibitors. US0124099A1; 2011
   Google Scholar
• Li Jun Li X, Catron KM. Ikkalpha and ikkβ specific inhibitors. US0088298A1; 2012
   Google Scholar
• Korea Ocean Research and Development Institute. Pharmaceutical composition for the prevention or treatment of inflammatory diseases or immune diseases containing ramalin. US0116324A1; 2013
   Google Scholar
• Yim JH, Kim CII, Lee SG, et al. Pharmaceutical composition for the prevention or treatment of inflammatory diseases or immune diseases containing ramalin. EP2578214A2; 2013
   Google Scholar
• Yim JH, Kim CII, Lee SG, et al. Composition pharmaceutique pour la prévention ou le traitement de maladies inflammatoires ou de maladies du système immunitaire, contenant de la ramaline. WO152671A2; 2011
   Google Scholar
• Yim JH, Kim IC, Lee SG, et al. Composition pharmaceutique pour la prévention ou le traitement de maladies inflammatoires ou de maladies du système immunitaire, contenant de la ramaline. WO152671A9; 2011
   Google Scholar
• Umezawa K, Ishikawa Y, Nishiyama S, et al. Pharmaceutical compositions. US0213001A1; 2011
   Google Scholar
• Umezawa K, Ishikawa Y, Nishiyama S, et al. Pharmaceutical compositions. US8524747B2; 2013
   Google Scholar
• Umezawa K, Ishikawa Y, Nishiyama S, et al. Pharmaceutical compositions. EP2308842A1; 2011
   Google Scholar
• Ahn KS, Kwon O-K, Oh SR, et al. Pharmaceutical composition for preventing or treating inflammatory diseases, allergic diseases or asthma, containing diospyros blancoi a. dc. extract as active ingredient. US0164395A1; 2013
   Google Scholar
• Ahn KS, Jang HY, Joung H, et al. Pharmaceutical composition for preventing or treating inflammatory diseases, allergic diseases or asthma, containing diospyros blancoi a. dc. extract as active ingredient. WO030137A2; 2012
   Google Scholar
• Yamaguchi M. NF-kappaB inhibitor. US0259895A1; 2013
   Google Scholar
• Won M, Jun JG, Yoo KY, et al. Dérivé de décursinol, procédé de production associé et composition pharmaceutique le contenant. WO1129516A1; 2011
   Google Scholar
• Tepe JJ, Satyamaheshwar P. NF-kappaB inhibitors and uses thereof. US8552206B2; 2013
   Google Scholar
• Davidson M, Arnett JF, Elshani S, Rongen R. Plant steroids and uses thereof. WO040441A1; 2013
   Google Scholar
• May MJ, Ghosh S. Anti-inflammatory compounds and uses thereof. US8217138B2; 2012
   Google Scholar
• May MJ, Ghosh S. Anti-inflammatory compounds and uses thereof. US8017726B2; 2011
   Google Scholar
• Tuckermann J, Rauch A, Ostermay S, Baschant U. Agent against glucocorticoid-induced osteoporosis. WO154413A1; 2011
   Google Scholar
• Tuckermann J, Rauch A, Ostermay S, Baschant U. Method for the prophylactic or therapeutic treatment of glucocorticoid-induced osteoporosis. US0171097A1; 2013
   Google Scholar
• Kwangju Womans University. Composition for inhibiting high glucose-induced inflammatory comprising fisetion or pharmaceutically acceptable salt thereof as an active ingredient. KR100027896A; 2013
   Google Scholar
• Kalinski P, Muthuswamy R. Tumor selective chemokine modulation. WO016297A2; 2013
   Google Scholar
• Beg AA, Enkemann SA, Chen D-T. Gene signature for the prediction of NFkappaB activity. WO067198A1; 2013
   Google Scholar
• Kelly D. Methods for treating an inflammatory disease of the bowel. US7998474B2; 2011
   Google Scholar
• Weinstein SD, Chen P, Murali Dhar TG, et al. Modulators of glucocorticoid receptor, AP-1, and/or NF-kappaB activity and use thereof. US8034940B2; 2011
   Google Scholar
• Murali Dhar TG, Xiao H-Y, Yang B. Modulators of the glucocorticoid receptor, AP-1, and/or NF-kappaB activity and use thereof. US8013004B2; 2011
   Google Scholar
• Murali Dhar TG, Xiao H-Y, Sheppeck JE. Modulators of glucocorticoid receptor, AP-1, and/or NF-kappaB activity and use thereof. US7994190B2; 2011
   Google Scholar
• Yang BV, Doweyko LM, Vaccaro W, et al. Modulators of glucocorticoid receptor, AP-1, and/or NF-kappaB activity and use thereof. US7968577B2; 2011
   Google Scholar
• Yang BV. Cyclopentathiophene modulators of the glucocorticoid receptor, AP-1, and/or NF-kappaB activity and use thereof. US8106046B2; 2012
   Google Scholar
• Duan J, Lu Z, Weinstein DS, Jiang B. Modulators of glucocorticoid receptor, AP-1, and/or NF-kappaB activity, and use thereof. US7888381B2; 2011
   Google Scholar
• Sheppeck JE, Gilmore JL, Murali Dhar TG, Xiao H-Y. Modulators of glucocorticoid receptor, AP-1, and/or NF-kappaB activity and use thereof. US8067447B2; 2011
   Google Scholar
• Sheppeck JE, Gilmore JL, Murali Dhar TG, et al. Modulators of glucocorticoid receptor, AP-1, and/or NF-kappaB activity and use thereof. US8198311B2; 2012
   Google Scholar
• McCall JM, Hoffman E, Nagaraju K. Non-hormonal steroid modulators of NF-kappaB for treatment of disease. US8207151B2; 2012
   Google Scholar
• Duan J, Weinstein DS, Jiang B. Fused heteroaryl modulators of glucocorticoid receptor, AP-1, and/or NF-kappaB activity and use thereof. US8304539B2; 2012
   Google Scholar
• Duan J, Jiang B. Indane modulators of glucocorticoid receptor, AP-1, and/or NF-kappaB activity and use thereof. US8324401B2; 2012
   Google Scholar
• Duan J, Weinstein DS, Jiang B. Fused heteroaryl modulators of glucocorticoid receptor, AP-1, and/or NF-kappaB activity and use thereof. US0002952A1; 2011
   Google Scholar
• Kufe DW, Kharbanda S. Inhibition of inflammation using antagonists of muc1. US0015138A1; 2011
   Google Scholar
• DiDonato JA, Hayakawa M, Rothwarf DM, et al. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature 1997;388:548-54
   PubMed Web of Science ®Google Scholar
• Takeda K, Takeuchi O, Tsujimura T, et al. Limb and skin abnormalities in mice lacking IKKalpha. Science 1999;284:313-16
   PubMed Web of Science ®Google Scholar
• Hu Y, Baud V, Delhase M, et al. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase. Science 1999;284:316-20
   PubMed Web of Science ®Google Scholar
• Li Q, Van Antwerp D, Mercurio F, et al. Severe Liver Degeneration in Mice Lacking the IkappaB Kinase 2 Gene. Science 1999;284:321-5
   PubMed Web of Science ®Google Scholar
• Zandi E, Rothwarf DM, Delhase M, et al. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKβ, NECESSARY for IkappaB phosphorylation and NF-kappaB activation. Cell 1997;91:243-52
   PubMed Web of Science ®Google Scholar
• Logeat F, Israël N, Ten R, et al. Inhibition of transcription factors belonging to the rel/NF-kappaB family by a trans dominant negative mutant. EMBO J 1991;10:1827-32
   PubMed Web of Science ®Google Scholar
• Li J, Li X, Yang J, et al. Methods for modulating ikkalpha activity. US0112284A1; 2011
   Google Scholar
• Ewha University-Industry Collaboration Foundation. Pharmaceutical composition for inhibiting abnormal proliferation of cells. WO096756A2; 2011
   Google Scholar
• Ewha University-Industry Collaboration Foundation. Pharmaceutical composition for inhibiting abnormal proliferation of cells. WO096756A3; 2011
   Google Scholar
• Ewha University-Industry Collaboration Foundation. Pharmaceutical composition for inhibiting abnormal proliferation of cells. WO096756A9; 2011
   Google Scholar
• Kang SW, Lee SY. Pharmaceutical composition for inhibiting abnormal proliferation of cells. US0308568; 2012
   Google Scholar
• Maclee Technology Inc. Use of regulator of calcineurin 1 for manufacturing medicament for treatment of diseases associated with increased NF-kappaB activity. WO 145890A1; 2012
   Google Scholar
• Li W. Use of regulator of calcineurin 1 for manufacturing medicament for treatment of diseases associated with increased NF-kappaB activity. EP2703006A1; 2014
   Google Scholar
• Cai D. Neural stem cell therapy for obesity and diabetes. WO116054A1; 2013
   Google Scholar
• Stark GR, Dermawan KT. Cancer treatment using tyrosine kinase and nf-kappab inhibitors. US0066465A1; 2014
   Google Scholar
• Hu W. Use of nibp polypeptides. WO046922A1; 2011
   Google Scholar
• Natarajan A, Chen Q, Bryant VC, Rajule R. Quinoxaline compounds and uses thereof. US0289041A1; 2013
   Google Scholar
• Bryant VC, Chaturvedi N, Chen Q, et al. Quinoxaline compounds and uses thereof. WO071414A2; 2012
   Google Scholar
• Kyorin Pharmaceutical Co LTD. Composé de dihydrothiéno[2,3-e]indazole. WO077502; 2011
   Google Scholar
• Manning A, Mercurio F, Amit S, et al. Compounds and methods for modulating activation of NF-kappaB. US8263326B2; 2011
   Google Scholar
• Li J, Li X, Yang J, et al. Methods for modulating IKKalpha activity. US8088915B2; 2012
   Google Scholar
• Zhang S, Won YK, Ong CN, et al. Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms. Curr Med Chem Anticancer Agents 2005;5:239-49
   PubMedGoogle Scholar
• García-Piñeres AJ, Lindenmeyer MT, Merfort I. Role of cysteine residues of p65/NFkappaB on the inhibition by the sesquiterpene lactone parthenolide and N-ethyl maleimide, and on its transactivating potential. Life Sci 2004;75:841-56
   PubMed Web of Science ®Google Scholar
• Liang MC, Bardhan S, Pace EA, et al. Inhibition of transcription factor NF-kappaB signaling proteins IKKbeta and p65 through specific cysteine residues by epoxyquinone A monomer: correlation with its anti-cancer cell growth activity. Biochem Pharmacol 2006;71:634-45
   PubMed Web of Science ®Google Scholar
• Morishita R, Sugimoto T, Aoki M, et al. In vivo transfection of cis element “decoy” against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 1997;3:894-9
   PubMed Web of Science ®Google Scholar
• Korea Research Institute of Bioscience and Biotechnology. Pharmaceutical composition containing olenolic acid acetate as an active ingredient for preventing or treating tlr- or il-6-mediated diseases. WO148247A2; 2012
   Google Scholar
• Lanzhou University. Cell model based on stat3 and NF-kappaB dual-signalling pathway as target for screening anti-tumour drug and construction and use thereof. WO087033A1; 2013
   Google Scholar
• Gilmore TD, Herscovitch M. Inhibitors of NF-kappaB Signalling 785 and counting. Oncogene 2006;25:6887-99
   PubMed Web of Science ®Google Scholar
• Bergmann M, Hart L, Lindsay M, et al. IkappaBalpha degradation and nuclear factor-kappaB DNA binding are insufficient for interleukin-1β and tumor necrosis factor-alpha-induced kappaB-dependent transcription. Requirement for an additional activation pathway. J Biol Chem 1998;273:6607-10
   PubMed Web of Science ®Google Scholar
• Marquez N, Sancho R, Bedoya LM, et al. Mesual, a natural occurring 4-phenylcoumarin, inhibits HIV-1 replication by targeting the NF-kappaB pathway. Antiviral Res 2005;66:137-45
   PubMed Web of Science ®Google Scholar
• University Industry Cooperation group of Kyung Hee University. Pharmaceutical composition for preventing and treating chronic obstructive pulmonary diseases, containing phyllostachys nigra munro var. henosis stapf extract as active ingredient. WO141501A1; 2013
   Google Scholar
• Shakhov A, Gudkov A. Methods of protecting against apoptosis using lipopeptides. US0045750A1; 2014
   Google Scholar
• Landry DW, O’Connor O, Deng S-X, et al. N-quinolin-benzensulfonamides and related compounds for the treatment of cancer, autoimmune disorders and inflammation. US0073668A1; 2014
   Google Scholar
• Morishita R, Ogiwara T, Sugimoto T, et al. For therapy and prophylaxis of ischemic diseases, inflammatory diseases, autoimmune diseases, cancer metastasis and invasion, and cachexia. US7871983B2; 2011
   Google Scholar
• Morishita R, Aoki M, Ogihara T, Kawasaki T. Decoy-containing pharmaceutical compositions and method of using the same. US8067388B2; 2011
   Google Scholar
• Benner R, Khan NA, Jacobs BCJ. Treatment of ischemic events. US8216998B2; 2012
   Google Scholar
• Bacher A, Eisenreich W, Eisner N, et al. Methods and compositions for inhibiting the nuclear factor kb pathway. WO011103A2; 2012
   Google Scholar
• Van Norren K, Dijk FJ, Berkhout B, Potappel BVL. Inhibition of NF-kappaB mediated virus replication with specific oligosaccharides. US0178671A1; 2012
   Google Scholar
• Gorenstein DG, Luxon BA, Leary J. Structure based and combinatorial selected oligonucleotide phosphorothioate and phosphorothioate aptameric targeting ap-1 transcription factors. US0212843; 2011
   Google Scholar
• Fedichev PO, Vinnik AA. Inhibitors of the pi3k/AKT/IKK/NF-kappaB signalling pathway, pharmaceutically acceptable salts thereof and compositions containing said inhibitors for the prophylaxis and treatment of viral diseases. WO147649A2; 2013
   Google Scholar
• Zhang Z, Rigas B. Inhibitors of NF-kappaB activity. US0004175A1; 2012
   Google Scholar
• Finberg RW, Kurt-Jones EA, Zhou S. Compounds for modulating TLR2. US0152251A1; 2011
   Google Scholar
• Finberg RW, Kurt-Jones EA, Zhou S. Compounds for modulating TLR2. US8609663B2; 2013
   Google Scholar
• Davidson L, Arnett JF, Elshani S, Rongen R. Plant steroids and uses thereof. WO040441; 2013
   Google Scholar
• Yi W, Hwang YS, Han SB, et al. Structure-activity relationship of chroman-2-carboxylic Acid N-Arylalkylamide Derivates. Yakhak hoeji 2013;57:426-31
   Google Scholar
• Choi M, Hwang YS, Kumar AS, et al. Design and synthesis of 3,4-dihydro-2H-benzo[h]chromene derivatives as potential NF-kappaB inhibitors. Bioorg Med Chem Lett 2014;24:2404-7
   PubMed Web of Science ®Google Scholar
• Kaur S, Southall MD, Zivin RA. Topical application of 1-hydroxyl-3,5-bis(4’hydroxyl styryl)benzene. US0004066A1; 2014
   Google Scholar
• Kaur S, Kirchner FJ, Zaleski E. Topical application of 1-hydroxyl 3,5-bis(4’hydroxyl styryl)benzene. US0004068A1; 2014
   Google Scholar
• Kaur S, Southall MD, Zivin RA. Topical application of 1-hydroxyl 3,5-bis(4’hydroxyl styryl)benzene. US0005275A1; 2014
   Google Scholar
• Kaur S, Mahmood K, Southall MD. Compositions comprising substituted phenols and topical application thereof. US0005276A1; 2014
   Google Scholar
• Guttridge DC, Baldwin AS. Methods of treating muscular wasting diseases using NF-kappaB activation inhibitors. US8426355B2; 2013
   Google Scholar
• Guttridge DC, Baldwin AS. Methods of treating muscular wasting diseases using NF-kappaB activation inhibitors. US0005127A1; 2014
   Google Scholar
• MCCall JM, Hoffman E, Nagaraju K. Non-hormonal steroid modulators of NF-kappaB for treatment of disease. WO127048A2; 2011
   Google Scholar
• MCCall JM, Hoffmanc E, Kanneboyina R, Damsker J. Non-hormonal steroid modulators of NF-kappaB for treatment of disease. WO082253A2; 2013
   Google Scholar
• Ehwa Womans University industry academy cooperation foundation. Antibody able to suppress osteoclast differentiation. WO176469A1; 2013
   Google Scholar
• Ulsan University. Composition comprising carbon monoxide or carbon monoxide donor for inhibition of bone loss. KR100026216A; 2012
   Google Scholar
• Okatsu TT, Sigmund JS, Peypooh AM, et al. Compound that can inhibit ubc13-uev interactions, pharmaceutical compositions and therapeutic uses. US0237529A1; 2013
   Google Scholar
• Fetz V, Knauer SK, Mann W, Stauber R. Nuclear export inhibitors. WO035147A1; 2012
   Google Scholar
• Chu GCY, Chung LWK, Wang R, Zhau HE. Cancer cell-derived receptor activator of the NF-kappaB ligand drives bone and soft tissue metastases. WO064967A2; 2012
   Google Scholar
• Robert JT, Gladstone PL, Allan AL, et al. Thiotungstate analogues and uses thereof. US0151022A1; 2011
   Google Scholar
• Whalen A, Staunton J, Steiger J, et al. Methods and compositions for treatment nf-kappab-mediated and alpha7 integrin-suppressed diseases. WO146819A2; 2011
   Google Scholar
• Finberg RW, Kurt-Jones EA, Zhou S. Compounds for modulating TLR2. WO062955A2; 2011
   Google Scholar
• Bogen B, Munthe L, Carlsen H, Blomhoff R. Triple transgenic mouse model of autoimmune disease and NF-kappaB in vivo imaging. US0126299A1; 2011
   Google Scholar
• Holzer F, Lee HH, Mahler M, Steinfeld U. Composition and drug containing omega-3 fatty acids, and a modulator. WO059158A1; 2012
   Google Scholar
• Wallach D, Makrishnan P, Shmushkovich T. Pharmaceutical compositions for treating diseases associated with NF-kappaB activity. US8338567B2; 2012
   Google Scholar
• Lavon I, Goldberg I, Amit S, et al. High susceptibility to bacterial infection, but no liver dysfunction, in mice compromised for hepatocyte NF-kappaB activation. Nat Med 2000;6:573-7
   PubMed Web of Science ®Google Scholar
• Hoffmann A, Baltimore D. Circuitry of nuclear factor kappaB signaling. Immunol Rev 2006;210:171-86
   PubMed Web of Science ®Google Scholar
• Behar M, Barken D, Werner SL, et al. The dynamics of signaling as a pharmacological target. Cell 2013;155:448-61
   PubMed Web of Science ®Google Scholar